Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Scordo

Showing results (1-10 of 179) with videos related to

Pageof 18
Sort By:
Blood Advances|October 5, 2024
The promises and potential pitfalls of pharmacokinetic model-based dosing in cellular therapyMichael Scordo
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 18, 2018
An Old Friend Is Trouble for Double-Expressor and Double-Hit LymphomaMichael Scordo
Blood|March 29, 2020
Compliments to complement blockade for TA-TMAMichael Scordo, Sergio Giralt
Blood Advances|November 27, 2024
Model-based dosing for better survival after transplantationJaap Jan Boelens, Michael Scordo
The Lancet. Haematology|August 24, 2024
Urgent need: evidence-based use of donor lymphocyte infusionsJaap Jan Boelens, Michael Scordo
British Journal of Haematology|February 13, 2020
A key step towards setting a benchmark for tackling transplant-associated thrombotic microangiopathyMichael Scordo, Sergio A Giralt
Cancer Immunology Research|June 2, 2023
Linking Body Composition and Nutritional Status with CAR T-cell EfficacyMariam T Nawas, Michael Scordo
Intensive Care Medicine|October 24, 2023
The EAS(E)IX of predicting sepsis after allogeneic hematopoietic cell transplantationCosmo Fowler, Michael Scordo, Sanjay Chawla
Bone Marrow Transplantation|March 12, 2024
Successful use of narsoplimab to treat allogeneic transplant-associated thrombotic microangiopathy while maintaining sirolimusMohammad Alhomoud, Michael Scordo, Miguel-Angel Perales
Current Opinion in Hematology|June 7, 2019
Hematopoietic-cell transplantation for lymphoma in the era of genetically engineered cellular therapy: it's not quite time to scrap the old vehicle for the new carMichael Scordo, Richard J Lin, Craig S Sauter
Pageof 18

Showing results (1-10 of 179) with videos related to

Sort By:
Pageof 18
Blood Advances|October 5, 2024
The promises and potential pitfalls of pharmacokinetic model-based dosing in cellular therapyMichael Scordo
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 18, 2018
An Old Friend Is Trouble for Double-Expressor and Double-Hit LymphomaMichael Scordo
Blood|March 29, 2020
Compliments to complement blockade for TA-TMAMichael Scordo, Sergio Giralt
Blood Advances|November 27, 2024
Model-based dosing for better survival after transplantationJaap Jan Boelens, Michael Scordo
The Lancet. Haematology|August 24, 2024
Urgent need: evidence-based use of donor lymphocyte infusionsJaap Jan Boelens, Michael Scordo
British Journal of Haematology|February 13, 2020
A key step towards setting a benchmark for tackling transplant-associated thrombotic microangiopathyMichael Scordo, Sergio A Giralt
Cancer Immunology Research|June 2, 2023
Linking Body Composition and Nutritional Status with CAR T-cell EfficacyMariam T Nawas, Michael Scordo
Intensive Care Medicine|October 24, 2023
The EAS(E)IX of predicting sepsis after allogeneic hematopoietic cell transplantationCosmo Fowler, Michael Scordo, Sanjay Chawla
Bone Marrow Transplantation|March 12, 2024
Successful use of narsoplimab to treat allogeneic transplant-associated thrombotic microangiopathy while maintaining sirolimusMohammad Alhomoud, Michael Scordo, Miguel-Angel Perales
Current Opinion in Hematology|June 7, 2019
Hematopoietic-cell transplantation for lymphoma in the era of genetically engineered cellular therapy: it's not quite time to scrap the old vehicle for the new carMichael Scordo, Richard J Lin, Craig S Sauter
Pageof 18